CD34 and Alzheimer disease: We found that increased CD34+CD133+ quartiles had a significantly dose-dependent association with decreased AD risk among participants who had HTN (P = 4.6 × 10−4, Figure 2E) and CMB (P = 0.01, Figure 2K).